-
Innovation Ranking
Innovation Ranking – SGS SA
SGS SA (SGS) provides inspection, verification, testing, certification, and quality assurance services. The company also provides risk management, consultancy, sustainability solutions, and training services. SGS inspects, samples, analyses, and monitors raw materials, components, and products for compliance with industrial standards and local regulatory requirements, including tax and duty. The company serves various industries including chemical, oil and gas, agriculture and food, construction, energy, life sciences, arts and culture, mining, public sector, logistics, industrial manufacturing, consumer goods and retail, environment, and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SG-2501 in Relapsed Multiple Myeloma Drug Details: SG-2501 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SG-2501 in Refractory Multiple Myeloma Drug Details: SG-2501 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Primary Systemic Amyloidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Primary Systemic Amyloidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SG-2501 in Primary Systemic Amyloidosis Drug Details: SG-2501 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SG-2501 in Chronic Lymphocytic Leukemia (CLL) Drug Details: SG-2501...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SG-2501 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: SG-2501...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SG-2501 in Diffuse Large B-Cell Lymphoma Drug Details: SG-2501...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SG-2501 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SG-2501 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SG-2501 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
SG Realty – SG Realty Shinsuna – Tokyo
The SG Realty – SG Realty Shinsuna – Tokyo involves the construction of a seven-story 86,768.49m2 logistics center on 3.34ha of land in Tokyo, Japan. Equip yourself with the essential tools needed to make informed and profitable decisions with our SG Realty – SG Realty Shinsuna – Tokyo report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain...
-
Thematic Analysis
NewAutomotive M&A Deals, Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Automotive Sector